This report contains a series of articles published by EP Vantage looking at the implications of Brexit for the life science industries.
They highlight the most important issues for the sector, which include the future of drug and medical device regulation outside of European frameworks and implications for intellectual property.
What Brexit means for life science funding and strategy
The UK by numbers
What Brexit means for drug regulation
What Brexit means for medtech regulation
What Brexit means for medtech patents
EP Vantage is Evaluate’s independent editorial team providing daily news, commentary and analysis driven by Evaluate data and forecasts.